Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Department of Pediatrics, Chutoen General Medical Center, Kakegawa, Japan.
Pediatr Dermatol. 2022 Jul;39(4):613-615. doi: 10.1111/pde.15028. Epub 2022 May 16.
Oral propranolol is recommended as the first-line agent for infantile hemangioma requiring systemic treatment. Life-threatening complications such as obstructive infantile hemangioma of the airway or infantile hepatic hemangioma associated with high-output congestive heart failure are major indications for the consideration of early treatment. We present the case of an infant with life-threatening diffuse neonatal hemangiomatosis, including airway obstruction due to subglottic hemangioma, heart failure due to multiple hepatic hemangiomas with portohepatic venous shunts, and severe anemia due to continuous gastrointestinal bleeding, in which treatment with intravenous propranolol proved successful.
口服普萘洛尔被推荐为需要全身治疗的婴儿血管瘤的一线药物。危及生命的并发症,如气道阻塞性婴儿血管瘤或伴有高输出量充血性心力衰竭的婴儿肝血管瘤,是早期治疗的主要指征。我们报告了一例危及生命的弥漫性新生儿血管瘤病婴儿,包括因声门下血管瘤导致的气道阻塞、多个肝血管瘤伴有门腔静脉分流导致的心衰以及持续胃肠道出血导致的严重贫血,静脉注射普萘洛尔治疗取得了成功。